Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03316521
Recruitment Status : Completed
First Posted : October 20, 2017
Last Update Posted : January 16, 2018
Sponsor:
Information provided by (Responsible Party):
Amyndas Pharmaceuticals S.A.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : November 30, 2017
Actual Study Completion Date : November 30, 2017
Publications: